Search Results - "Tsuneizumi, M" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)

A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)

by Sakai, H., Tsurutani, J., Ozaki, Y., Ishiguro, H., Nozawa, K., Yamanaka, T., Aogi, K., Matsumoto, K., Iwasa, T., Tokiwa, M., Tsuneizumi, M., Miyoshi, Y., Kitagawa, C., Yamamoto, M., Takano, Y., Imamura, C.K., Chiba, Y., Takiguchi, D., Ezumi, T., Takano, T.
Published in Annals of oncology (14.09.2024)

Get full text

Journal Article

Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing

Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing

by Takeshita, T., Iwamoto, T., Niikura, N., Watanabe, K., Kikawa, Y., Kobayashi, K., Iwakuma, N., Okamura, T., Tada, H., Ozaki, S., Okuno, T., Toh, U., Yamamoto, Y., Tsuneizumi, M., Ishiguro, H., Masuda, N., Saji, S.
Published in ESMO open (01.04.2024)

Get full text

Journal Article

465. The role of single-photon emission computed tomography in sentinel lymph node biopsy, denying taking too many lymph nodes a lot

465. The role of single-photon emission computed tomography in sentinel lymph node biopsy, denying taking too many lymph nodes a lot

by Takayanagi, H, Nakagami, K, Tsuneizumi, M, Fukuchi, K, Haramiishi, K
Published in European journal of surgical oncology (01.11.2014)

Get full text

Journal Article

Comparison between triplet antiemetic study (TTT) and doublet antiemetic study (PROTECT): insights into the mechanisms of serotonin and aprepitant actions in chemotherapy induced nausea and vomiting

Comparison between triplet antiemetic study (TTT) and doublet antiemetic study (PROTECT): insights into the mechanisms of serotonin and aprepitant actions in chemotherapy induced nausea and vomiting

by Kutomi, G, Saito, M, Tsuneizumi, M, Ogata, H, Kawai, Y, Hosoya, K, Sugisaki, K, Katsumata, N, Nitta, Y, Matsuoka, J
Published in Breast (Edinburgh) (01.03.2017)

Get full text

Journal Article

Identification of DMC1, a novel gene in the TOC region on 17q25.1 that shows loss of expression in multiple human cancers

Identification of DMC1, a novel gene in the TOC region on 17q25.1 that shows loss of expression in multiple human cancers

by Harada, H, Nagai, H, Tsuneizumi, M, Mikami, I, Sugano, S, Emi, M
Published in Journal of human genetics (01.01.2001)

Get full text

Journal Article

1816O A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)

1816O A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)

by Sakai, H., Tsurutani, J., Ozaki, Y., Ishiguro, H., Nozawa, K., Yamanaka, T., Kameoka, H., Matsumoto, K., Iwasa, T., Tokiwa, M., Tsuneizumi, M., Miyoshi, Y., Kitagawa, C., Yamamoto, M., Takano, Y., Imamura, C.K., Chiba, Y., Takiguchi, D., Ezumi, T., Takano, T.
Published in Annals of oncology (01.09.2024)

Get full text

Journal Article

304P Impact of estrogen receptor positivity for adjuvant endocrine therapy in luminal T1a/bN0M0 breast cancer: A multi-institutional retrospective observational study

304P Impact of estrogen receptor positivity for adjuvant endocrine therapy in luminal T1a/bN0M0 breast cancer: A multi-institutional retrospective observational study

by Sasada, S., Takahashi, Y., Terata, K., Kida, K., Sagara, Y., Ueno, T., Anan, K., Suto, A., Kanbayashi, C.K., M. takahashi, Nakamura, R., Ishiba, T., Tsuneizumi, M., Nishimura, S., Naito, Y., Hara, F., Iwata, H., Shien, T.
Published in Annals of oncology (01.09.2024)

Get full text

Journal Article

359P Overall survival of palbociclib (PAL) + endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study

359P Overall survival of palbociclib (PAL) + endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study

by Nakayama, T., Nagai, S.E., Hattori, M., Yoshinami, T., Masuda, H., Okamura, T., Watanabe, K-I., Tsuneizumi, M., Takabatake, D., Harao, M., Yasojima, H., Oshiro, C., Iwase, M., Yamaguchi, M., Sangai, T., Sasada, S., Ishida, T., Futamura, M., Kosaka, N., Masuda, N.
Published in Annals of oncology (01.09.2024)

Get full text

Journal Article

373P Quality-of-life outcomes in patients with HER2-positive, locally advanced or metastatic breast cancer treated with eribulin mesylate in combination with trastuzumab and pertuzumab in the phase III JBCRG-M06/EMERALD study

373P Quality-of-life outcomes in patients with HER2-positive, locally advanced or metastatic breast cancer treated with eribulin mesylate in combination with trastuzumab and pertuzumab in the phase III JBCRG-M06/EMERALD study

by Masuda, N., Saji, S., Iwatani, T., Takano, T., Koizumi, K., Sagara, Y., Naito, Y., Tsuneizumi, M., Yoshimura, A., Takahashi, M., Tsurutani, J., Kitada, M., Tada, H., Higuchi, T., Kojima, Y., Kadoya, T., Hasegawa, H., Uchida, Y., Morita, S., Yamashita, T.
Published in Annals of oncology (01.09.2024)

Get full text

Journal Article

Down-regulation in human cancers of DRHC, a novel helicase-like gene from 17q25.1 that inhibits cell growth

Down-regulation in human cancers of DRHC, a novel helicase-like gene from 17q25.1 that inhibits cell growth

by Nagai, H., Yabe, A., Mine, N., Mikami, I., Fujiwara, H., Terada, Y., Hirano, A., Tsuneizumi, M., Yokota, T., Emi, M.
Published in Cancer letters (10.04.2003)

Get full text

Journal Article

421P Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer

421P Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer

by Iwamoto, T., Watanabe, K-I., Niikura, N., Takeshita, T., Kikawa, Y., Kobayashi, K., Iwakuma, N., Okamura, T., Tada, H., Ozaki, S., Okuno, T., Toh, U., Yamamoto, Y., Tsuneizumi, M., Ishiguro, H., Masuda, N., Saji, S.
Published in Annals of oncology (01.10.2023)

Get full text

Journal Article

228P Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2-negative breast cancer after progression to fulvestrant monotherapy: JBCRG- M07 (FUTURE trial)

228P Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2-negative breast cancer after progression to fulvestrant monotherapy: JBCRG- M07 (FUTURE trial)

by Watanabe, K., Niikura, N., Kikawa, Y., Oba, M., Kobayashi, K., Tada, H., Ozaki, S., Toh, U., Yamamoto, Y., Tsuneizumi, M., Okuno, T., Iwakuma, N., Takeshita, T., Iwamoto, T., Ishiguro, H., Masuda, N., Saji, S.
Published in Annals of oncology (01.09.2022)

Get full text

Journal Article

Abstract OT2-01-05: A randomized controlled trial comparing post-operative intensive follow-up with standard follow-up in high-risk breast cancer patients (JCOG1204: INSPIRE)

Abstract OT2-01-05: A randomized controlled trial comparing post-operative intensive follow-up with standard follow-up in high-risk breast cancer patients (JCOG1204: INSPIRE)

by Hojo, T, Masuda, N, Shibata, T, Mizutani, T, Shien, T, Kinoshita, T, Iwatani, T, Kanbayashi, C, Kitagawa, D, Tsuneizumi, M, Iwata, H
Published in Cancer research (Chicago, Ill.) (15.02.2019)

Get full text

Journal Article

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: Results of single arm phase IV COMACHI study

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: Results of single arm phase IV COMACHI study

by Masuda, N., Ohtani, S., Nagai, S., Takashima, S., Yamaguchi, M., Tsuneizumi, M., Komoike, Y., Osako, T., Ito, Y., Ikeda, M., Ishida, K., Nakayama, T., Takashima, T., Asakawa, T., Matsumoto, S., Shimizu, D., Takahashi, M.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

353P - Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: Results of single arm phase IV COMACHI study

353P - Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: Results of single arm phase IV COMACHI study

by Masuda, N., Ohtani, S., Nagai, S., Takashima, S., Yamaguchi, M., Tsuneizumi, M., Komoike, Y., Osako, T., Ito, Y., Ikeda, M., Ishida, K., Nakayama, T., Takashima, T., Asakawa, T., Matsumoto, S., Shimizu, D., Takahashi, M.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

353PPertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: Results of single arm phase IV COMACHI study

353PPertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer: Results of single arm phase IV COMACHI study

by Masuda, N, Ohtani, S, Nagai, S, Takashima, S, Yamaguchi, M, Tsuneizumi, M, Komoike, Y, Osako, T, Ito, Y, Ikeda, M, Ishida, K, Nakayama, T, Takashima, T, Asakawa, T, Matsumoto, S, Shimizu, D, Takahashi, M
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

Mediastinal recurrence of breast cancer suspecting mediastinal fibrosis

Mediastinal recurrence of breast cancer suspecting mediastinal fibrosis

by Ishibashi, H, Ohta, S, Hirose, M, Matsunuma, R, Tsuneizumi, M, Nakagami, K, Shibuya, K, Tanio, N, Nakajima, N
Published in Kyobu geka. The Japanese journal of thoracic surgery (01.11.2006)

Get more information

Journal Article

Durable complete response in HER2-positive breast cancer: A multicenter retrospective analysis

Durable complete response in HER2-positive breast cancer: A multicenter retrospective analysis

by Shimomura, A., Niikura, N., Fukatsu, Y., Sawaki, M., Ogiya, R., Yasojima, H., Fujisawa, T., Yamamoto, M., Tsuneizumi, M., Kitani, A., Watanabe, J., Matsui, A., Takahashi, Y., Takashima, S., Shien, T., Tamura, K., Saji, S., Masuda, N., Tokuda, Y., Iwata, H.
Published in Annals of oncology (01.09.2017)

Get full text

Journal Article

Abstract P5-11-03: Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients – according to recent multi-institutional double-blind randomized clinical research on the AC regimen

Abstract P5-11-03: Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients – according to recent multi-institutional double-blind randomized clinical research on the AC regimen

by Ogata, H, Saito, M, Tsuneizumi, M, Kutomi, G, Hosoya, K, Kawai, Y, Sugizaki, K, Katsumata, N, Senuma, K, Kitabatake, T, Suda, M, Uomori, T, Miura, K, Kurata, M, Nitta, Y, Yonemoto, N, Matsuoka, J
Published in Cancer research (Chicago, Ill.) (15.02.2017)

Get full text

Journal Article

P013 - Comparison between triplet antiemetic study (TTT) and doublet antiemetic study (PROTECT): insights into the mechanisms of serotonin and aprepitant actions in chemotherapy induced nausea and vomiting

P013 - Comparison between triplet antiemetic study (TTT) and doublet antiemetic study (PROTECT): insights into the mechanisms of serotonin and aprepitant actions in chemotherapy induced nausea and vomiting

by Kutomi, G., Saito, M., Tsuneizumi, M., Ogata, H., Kawai, Y., Hosoya, K., Sugisaki, K., Katsumata, N., Nitta, Y., Matsuoka, J.
Published in Breast (Edinburgh) (01.03.2017)

Get full text

Journal Article